TY - JOUR
T1 - Th17 cells in primary Sjogren's syndrome
T2 - Pathogenicity and plasticity
AU - Verstappen, Gwenny M.
AU - Corneth, Odilia B. J.
AU - Bootsma, Hendrika
AU - Kroese, Frans G. M.
PY - 2018/2
Y1 - 2018/2
N2 - Th17 cells play an important physiological role at mucosal barriers, and are involved in inflammatory responses to pathogens. Th17 cells and their signature cytokine IL-17 are also present in salivary gland lesions of primary Sjogren's syndrome (pSS) patients and can be elevated in their peripheral blood. In pSS patients, clear correlations between increased Th17 cell activity and symptoms of the disease have not been found, but Th17 cells may contribute to disease progression, for example by supporting autoreactive B cell responses. In mouse models of pSS, Th17 cells play an important role in pathogenesis, particularly at disease onset, when there is a disturbed balance between T effector and T regulatory cells. Studying the pathogenicity of Th17 cells in humans is complicated due to the plasticity of this cell subset, allowing them to obtain different effector functions depending on the local environment. Th17 cells can develop towards Th17.1 cells, producing both IL-17 and IFN-gamma, or even towards Th1-like cells producing IFN-gamma in the absence of IL-17. These effector subsets may be more pathogenic than bona fide Th17 cells. Co-expression of IFN-y by Th17 cells has been shown to promote chronic inflammation in several auto immune diseases and may also contribute to pSS pathogenesis. In line with the noticeable role of IL-17 in pSS mouse models, interference with Th17 cell generation, recruitment or effector functions (e.g. IL-17 inhibition) can prevent or ameliorate disease in these models. Therapies targeting Th17 cells or IL-17 have not been tested so far in pSS patients, although treatment with rituximab seems to lower local and systemic IL-17 protein levels, and to a lesser extent also chemokine receptor-defined Th17 cells. In this review we discuss current knowledge of pathogenicity and plasticity of Th17 cells in human pSS and murine models of pSS. We postulate that plasticity towards Th17.1 cells in pSS may enhance pathogenicity of Th17 cells at the main target sites of the disease, i.e. salivary and lacrimal glands. (C) 2017 The Authors. Published by Elsevier Ltd.
AB - Th17 cells play an important physiological role at mucosal barriers, and are involved in inflammatory responses to pathogens. Th17 cells and their signature cytokine IL-17 are also present in salivary gland lesions of primary Sjogren's syndrome (pSS) patients and can be elevated in their peripheral blood. In pSS patients, clear correlations between increased Th17 cell activity and symptoms of the disease have not been found, but Th17 cells may contribute to disease progression, for example by supporting autoreactive B cell responses. In mouse models of pSS, Th17 cells play an important role in pathogenesis, particularly at disease onset, when there is a disturbed balance between T effector and T regulatory cells. Studying the pathogenicity of Th17 cells in humans is complicated due to the plasticity of this cell subset, allowing them to obtain different effector functions depending on the local environment. Th17 cells can develop towards Th17.1 cells, producing both IL-17 and IFN-gamma, or even towards Th1-like cells producing IFN-gamma in the absence of IL-17. These effector subsets may be more pathogenic than bona fide Th17 cells. Co-expression of IFN-y by Th17 cells has been shown to promote chronic inflammation in several auto immune diseases and may also contribute to pSS pathogenesis. In line with the noticeable role of IL-17 in pSS mouse models, interference with Th17 cell generation, recruitment or effector functions (e.g. IL-17 inhibition) can prevent or ameliorate disease in these models. Therapies targeting Th17 cells or IL-17 have not been tested so far in pSS patients, although treatment with rituximab seems to lower local and systemic IL-17 protein levels, and to a lesser extent also chemokine receptor-defined Th17 cells. In this review we discuss current knowledge of pathogenicity and plasticity of Th17 cells in human pSS and murine models of pSS. We postulate that plasticity towards Th17.1 cells in pSS may enhance pathogenicity of Th17 cells at the main target sites of the disease, i.e. salivary and lacrimal glands. (C) 2017 The Authors. Published by Elsevier Ltd.
KW - Sjogren's syndrome
KW - Th17 cells
KW - IL-17
KW - Plasticity
KW - Autoimmunity
KW - REGULATORY T-CELLS
KW - SALIVARY-GLANDS
KW - AUTOIMMUNE EXOCRINOPATHY
KW - RHEUMATOID-ARTHRITIS
KW - HELPER-CELLS
KW - PROINFLAMMATORY CYTOKINES
KW - LYMPHOID NEOGENESIS
KW - INTERFERON-GAMMA
KW - PERIPHERAL-BLOOD
KW - EPITHELIAL-CELLS
U2 - 10.1016/j.jaut.2017.11.003
DO - 10.1016/j.jaut.2017.11.003
M3 - Review article
SN - 0896-8411
VL - 87
SP - 16
EP - 25
JO - Journal of Autoimmunity
JF - Journal of Autoimmunity
ER -